BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29334836)

  • 1. SNF5 deficiency induces apoptosis resistance by repressing SATB1 expression in Sézary syndrome.
    Li Y; Wang J; Yu M; Wang Y; Zhang H; Yin J; Li Z; Li T; Yan H; Li F; Wang X
    Leuk Lymphoma; 2018 Oct; 59(10):2405-2413. PubMed ID: 29334836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription.
    Wang Y; Su M; Zhou LL; Tu P; Zhang X; Jiang X; Zhou Y
    Blood; 2011 Apr; 117(14):3826-35. PubMed ID: 21270445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of MYC by the SMARCB1 tumor suppressor.
    Weissmiller AM; Wang J; Lorey SL; Howard GC; Martinez E; Liu Q; Tansey WP
    Nat Commun; 2019 May; 10(1):2014. PubMed ID: 31043611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice.
    Harro CM; Perez-Sanz J; Costich TL; Payne KK; Anadon CM; Chaurio RA; Biswas S; Mandal G; Rigolizzo KE; Sprenger KB; Mine JA; Showe LC; Yu X; Liu K; Rodriguez PC; Pinilla-Ibarz J; Sokol L; Conejo-Garcia JR
    J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33270606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased DNA damage sensitivity and apoptosis in cells lacking the Snf5/Ini1 subunit of the SWI/SNF chromatin remodeling complex.
    Klochendler-Yeivin A; Picarsky E; Yaniv M
    Mol Cell Biol; 2006 Apr; 26(7):2661-74. PubMed ID: 16537910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low SATB1 Expression Promotes IL-5 and IL-9 Expression in Sézary Syndrome.
    Herrera A; Fredholm S; Cheng A; Mimitou EP; Seffens A; Bar-Natan M; Sun A; Latkowski JA; Willerslew-Olsen A; Buus TB; Gluud M; Krejsgaard T; Torres-Rusillo S; Bonefeld CM; Woetmann A; Geisler C; Geskin LJ; Ouyang Z; Smibert P; Ødum N; Koralov SB
    J Invest Dermatol; 2020 Mar; 140(3):713-716. PubMed ID: 31465740
    [No Abstract]   [Full Text] [Related]  

  • 7. [Changes in gene expression profiles in multiple myeloma cells after knocking-down SNF5, a core subunit of SWI/SNF complex].
    Xie Y; Xu Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 May; 33(5):667-71. PubMed ID: 23688984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis.
    Han HJ; Russo J; Kohwi Y; Kohwi-Shigematsu T
    Nature; 2008 Mar; 452(7184):187-93. PubMed ID: 18337816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Special AT-rich Sequence Binding Protein 1 (SATB1) and its role in solid tumors.
    Frömberg A; Engeland K; Aigner A
    Cancer Lett; 2018 Mar; 417():96-111. PubMed ID: 29306014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation.
    Isakoff MS; Sansam CG; Tamayo P; Subramanian A; Evans JA; Fillmore CM; Wang X; Biegel JA; Pomeroy SL; Mesirov JP; Roberts CW
    Proc Natl Acad Sci U S A; 2005 Dec; 102(49):17745-50. PubMed ID: 16301525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of SATB1 expression with clinical course of cutaneous T-cell lymphomas.
    Grzanka A; Grzanka D; Gagat M; Tadrowski T; Sokołowska-Wojdyło M; Marszałek A; Placek W
    Pol J Pathol; 2012 Jun; 63(2):101-5. PubMed ID: 22864778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is SATB1 a master regulator in breast cancer growth and metastasis?
    Zheng J
    Womens Health (Lond); 2008 Jul; 4(4):329-32. PubMed ID: 19072498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SMARCB1 Deficiency Integrates Epigenetic Signals to Oncogenic Gene Expression Program Maintenance in Human Acute Myeloid Leukemia.
    Chatterjee SS; Biswas M; Boila LD; Banerjee D; Sengupta A
    Mol Cancer Res; 2018 May; 16(5):791-804. PubMed ID: 29483235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR aptamer-conjugated liposome-polycation-DNA complex for targeted delivery of SATB1 small interfering RNA to choriocarcinoma cells.
    Dong J; Cao Y; Shen H; Ma Q; Mao S; Li S; Sun J
    Biomed Pharmacother; 2018 Nov; 107():849-859. PubMed ID: 30142547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells.
    Frömberg A; Rabe M; Oppermann H; Gaunitz F; Aigner A
    BMC Cancer; 2017 Jan; 17(1):3. PubMed ID: 28049521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer.
    Selinger CI; Cooper WA; Al-Sohaily S; Mladenova DN; Pangon L; Kennedy CW; McCaughan BC; Stirzaker C; Kohonen-Corish MR
    J Thorac Oncol; 2011 Jul; 6(7):1179-89. PubMed ID: 21597389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple effects of the special AT-rich binding protein 1 (SATB1) in colon carcinoma.
    Frömberg A; Rabe M; Aigner A
    Int J Cancer; 2014 Dec; 135(11):2537-46. PubMed ID: 24729451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wnt/β-catenin signaling regulated SATB1 promotes colorectal cancer tumorigenesis and progression.
    Mir R; Pradhan SJ; Patil P; Mulherkar R; Galande S
    Oncogene; 2016 Mar; 35(13):1679-91. PubMed ID: 26165840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulating the Expression Strength of the Baculovirus/Insect Cell Expression System: A Toolbox Applied to the Human Tumor Suppressor SMARCB1/SNF5.
    Golas MM; Jayaprakash S; Le LTM; Zhao Z; Heras Huertas V; Jensen IS; Yuan J; Sander B
    Mol Biotechnol; 2018 Nov; 60(11):820-832. PubMed ID: 30178299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SATB1 is a Novel Molecular Target for Cancer Therapy.
    Ding M; Pan J; Guo Z; Liu Q; Yang C; Mao L
    Cancer Invest; 2018 Jan; 36(1):28-36. PubMed ID: 29381393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.